Differences in recurrence and survival of extremity liposarcoma subtypes
- PMID: 29673808
- DOI: 10.1016/j.ejso.2018.03.028
Differences in recurrence and survival of extremity liposarcoma subtypes
Abstract
Background: Liposarcomas can be divided into four subtypes and are most frequently located in the extremities. There are currently no studies comparing the clinical outcomes, such as local recurrence and distant metastasis, between the distinct subtypes of primary LPS of the extremity specifically.
Methods: Retrospective databases of two expertise centres (Rotterdam-R, Warsaw-W) of patients with liposarcoma located in the extremities from 1985 to 2015 were used to analyse 5-year local recurrence-free survival (5y-LRFS), 5-year distant metastasis-free survival (5y-DMFS) and 5-year overall survival (5y-OS).
Results: We identified 456 patients: 192 well-differentiated liposarcomas (WDLPS), 172 myxoid liposarcomas (MLPS), 54 pleomorphic liposarcomas (PLPS), 23 dedifferentiated liposarcomas (DDLPS) and 15 other subtypes. The frequency of (neo)adjuvant radiotherapy (R: 34.5% vs. W: 78.4%) and R0-resections (R: 41.0% vs. W: 84.1%) differed between the datasets. Local recurrences (LR) were observed most frequently in DDLPS (5y-LRFS 62.4%), followed by PLPS (71.4%), WDLPS (77.0%) and MLPS (84.5%, p = 0.054). Distant metastases (DM) were most commonly observed in PLPS (5y-DMFS 46.9%), followed by MLPS (74.0%), DDLPS (86.3%) and WDLPS (97.3%). 5y-OS was poorest in patients with PLPS (47.6%) and DDLPS (54.4%), followed by MLPS (79.7%) and WDLPS (92.4%, p < 0.001). Male gender significantly increased the risk of LR and DM. The subtypes MLPS and PLPS were significant prognostic factors for DM and OS. Additionally, DDLPS and age had significant impact on OS.
Conclusion: In the largest cohort of extremity LPS patients reported to date, LPS subtypes show distinct patterns of LR, DM and OS, stressing that 'extremity LPS' is not a single entity.
Keywords: Extremity; Liposarcoma; Recurrence; Survival; Treatment.
Copyright © 2018 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.
Similar articles
-
Predictors of outcomes in patients with primary retroperitoneal dedifferentiated liposarcoma undergoing surgery.J Am Coll Surg. 2014 Feb;218(2):206-17. doi: 10.1016/j.jamcollsurg.2013.10.009. Epub 2013 Oct 25. J Am Coll Surg. 2014. PMID: 24315890
-
Influence of age and subtype in outcome of operable liposarcoma.Radiol Med. 2019 Apr;124(4):290-300. doi: 10.1007/s11547-018-0958-4. Epub 2018 Nov 12. Radiol Med. 2019. PMID: 30421387
-
Impact of primary tumor location on outcome of liposarcoma patients, a retrospective cohort study.Eur J Surg Oncol. 2019 Dec;45(12):2437-2442. doi: 10.1016/j.ejso.2019.08.026. Epub 2019 Aug 31. Eur J Surg Oncol. 2019. PMID: 31493984
-
An overview on liposarcoma subtypes: Genetic alterations and recent advances in therapeutic strategies.J Mol Histol. 2024 Jun;55(3):227-240. doi: 10.1007/s10735-024-10195-4. Epub 2024 May 2. J Mol Histol. 2024. PMID: 38696048 Review.
-
Histology driven systemic therapy of liposarcoma-ready for prime time?Transl Gastroenterol Hepatol. 2018 Nov 23;3:96. doi: 10.21037/tgh.2018.11.01. eCollection 2018. Transl Gastroenterol Hepatol. 2018. PMID: 30603732 Free PMC article. Review.
Cited by
-
Recurrent metastatic retroperitoneal dedifferentiated liposarcoma: a case report and literature review.BMC Urol. 2023 Apr 24;23(1):63. doi: 10.1186/s12894-023-01252-3. BMC Urol. 2023. PMID: 37095466 Free PMC article. Review.
-
Development and validation of a novel prognostic model for long-term overall survival in liposarcoma patients: a population-based study.J Int Med Res. 2020 Dec;48(12):300060520975882. doi: 10.1177/0300060520975882. J Int Med Res. 2020. PMID: 33296604 Free PMC article.
-
Combination of immune checkpoint inhibitors and anthracyclines as a potential first-line regimen for dedifferentiated liposarcoma: systematic review and meta-analysis.Cancer Immunol Immunother. 2025 Apr 21;74(6):179. doi: 10.1007/s00262-025-04007-1. Cancer Immunol Immunother. 2025. PMID: 40257618 Free PMC article.
-
Histomorphological and molecular characteristics of liposarcoma (Review).Oncol Lett. 2025 Jul 21;30(4):454. doi: 10.3892/ol.2025.15200. eCollection 2025 Oct. Oncol Lett. 2025. PMID: 40747377 Free PMC article. Review.
-
Giant retroperitoneal liposarcoma with multiple organ involvement: a case report and literature review.BMC Nephrol. 2024 Aug 29;25(1):281. doi: 10.1186/s12882-024-03701-z. BMC Nephrol. 2024. PMID: 39210338 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources